Suppr超能文献

维拉帕米在体外可直接抑制肾上腺线粒体合成醛固酮。

Verapamil directly inhibits aldosterone synthesis by adrenal mitochondria in vitro.

作者信息

Blanchouin-Emeric N, Zenatti M, Defaye G, Aupetit B

机构信息

Service de Biochimie Médicale, Faculté de Médecine, Pitié-Salpétrière, Paris, France.

出版信息

J Steroid Biochem. 1988;30(1-6):453-6. doi: 10.1016/0022-4731(88)90141-0.

Abstract

The action of verapamil, a calcium channel blocker, on the last step of aldosterone biosynthesis (transformation of 18-hydroxycorticosterone into aldosterone) was studied using duck adrenal mitochondria in the absence of regulatory factors. Results show that 10(-5) M verapamil inhibits the transformation of 18-hydroxycorticosterone into aldosterone by 52.8%. Moreover, our findings show that verapamil induces only a slight inhibition of respiratory capacity without action on respiratory control and does not displace 18-hydroxycorticosterone from cytochrome P450 11 beta which catalyses the reaction. Thus, this study does not explain the mechanism of inhibition induced by verapamil on the last step of aldosterone synthesis but it is of interest to note, for clinical use, that this inhibition is not linked to regulatory factors of aldosterone production. Since primary hyperaldosteronisms are characterized by their independence vis-á-vis regulatory factors, administration of verapamil may be particularly interesting for treatment of primary hyperaldosteronisms.

摘要

在无调节因子的情况下,利用鸭肾上腺线粒体研究了钙通道阻滞剂维拉帕米对醛固酮生物合成最后一步(18 - 羟皮质酮转化为醛固酮)的作用。结果显示,10(-5) M的维拉帕米可使18 - 羟皮质酮向醛固酮的转化受到52.8%的抑制。此外,我们的研究结果表明,维拉帕米仅对呼吸能力产生轻微抑制,对呼吸控制无作用,且不会从催化该反应的细胞色素P450 11β上置换18 - 羟皮质酮。因此,本研究并未解释维拉帕米对醛固酮合成最后一步的抑制机制,但值得注意的是,从临床应用角度来看,这种抑制与醛固酮产生的调节因子无关。由于原发性醛固酮增多症的特点是其对调节因子具有独立性,维拉帕米的给药对于原发性醛固酮增多症的治疗可能特别有意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验